Brain-enriched microRNAs are also being studied as biomarkers in neurodevelopmental disorders, including Rett syndrome for prognosticating disease severity. Because the degree of change in specific microRNA signatures tracks with clinical severity scores and disease progression, the test offers a minimally invasive, objective way to gauge how severely a patient is affected and to monitor response to treatment over time.